2024-11-05 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis

### 1. Performance Overview

**Company Overview:** Johnson & Johnson is a multinational pharmaceutical, medical device, and consumer packaged goods company. 

**Performance vs. S&P 500 (VOO):**

* **JNJ Cumulative Return:** 31.91%
* **VOO Cumulative Return:** 131.28%
* **Difference:** -99.37%
* **Relative Divergence:** 5.34% (This means JNJ's performance has been lower than VOO by 99.37% and its relative position is at the 5.34% percentile of its historical range.)

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|---|---|---|---|---|
| 2015 | -1.7% | 10.1% | -0.9% | 0.8 |
| 2016 | 14.7% | 9.3% | 3.3% | 0.5 |
| 2017 | 20.6% | 5.3% | 2.0% | 0.5 |
| 2018 | -7.3% | 17.5% | -0.3% | 0.8 |
| 2019 | 14.2% | 10.6% | -14.4% | 0.5 |
| 2020 | 7.8% | 27.5% | -7.3% | 0.7 |
| 2021 | 9.3% | 12.1% | -19.5% | 0.4 |
| 2022 | 3.0% | 12.1% | 23.0% | 0.3 |
| 2023 | -12.0% | 16.6% | -36.8% | 0.3 |
| 2024 | -1.1% | 10.9% | -21.8% | -0.1 |

* **CAGR:** JNJ has shown a relatively stable CAGR over the past 10 years, with a slight decline in recent years.
* **MDD:**  The maximum drawdown in 2020 highlights the impact of market volatility on the stock.
* **Alpha:** JNJ has generally exhibited negative alpha, suggesting it has underperformed the market.
* **Beta:** JNJ's beta fluctuates but generally remains below 1, indicating a lower volatility compared to the market.

### 2. Recent Price Action

* **Closing Price:** 158.24 (Last-market: 158.25)
* **5-day Moving Average:** 159.79
* **20-day Moving Average:** 161.96
* **60-day Moving Average:** 162.68

JNJ's stock price is currently below its 5-day, 20-day, and 60-day moving averages, indicating a potential downtrend.

### 3. Technical Indicators

* **RSI:** 32.74 (Below 50) - Suggests JNJ is currently in oversold territory.
* **PPO:** -0.29 (Negative) - Shows that the momentum of the price is declining.
* **Delta_Previous_Relative_Divergence (20-day):** -1.22 (Negative) - Suggests a short-term downtrend.
* **Expected Return:** 0.0% - Over a long-term (2 years or more) investment horizon, JNJ is expected to deliver a similar return to the S&P 500.

**Note:**  If the price were to significantly increase, it could indicate a sudden upward trend (a "bounce"). Conversely, a substantial decrease could signify a sharp downturn (a "sell-off"). 

### 4. Recent Earnings & Outlook

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-23 | 1.12 | $22.47 B |
| 2024-07-25 | 1.95 | $22.45 B |
| 2024-05-01 | 1.35 | $21.38 B |
| 2024-02-16 | 1.68 | $21.39 B |
| 2023-10-27 | 10.32 | $21.35 B |

* **Latest Earnings:**  JNJ's recent earnings have fallen short of analyst expectations, potentially contributing to the stock's decline. 
* **Outlook:**  Analysts are expecting JNJ to continue to face challenges in the coming quarters due to increasing competition and pressure on pricing within the pharmaceutical industry. 

### 5. Financial Information

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $22.47B | 69.01% |
| 2024-06-30 | $22.45B | 69.40% |
| 2024-03-31 | $21.38B | 69.55% |
| 2023-12-31 | $21.39B | 68.23% |
| 2023-09-30 | $21.35B | 69.06% |

* JNJ continues to maintain strong profit margins, despite some recent fluctuation. 

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $70.16B | 3.84% |
| 2024-06-30 | $71.54B | 6.55% |
| 2024-03-31 | $70.02B | 4.65% |
| 2023-12-31 | $68.77B | 5.89% |
| 2023-09-30 | $71.23B | 36.54% |

* JNJ maintains a solid equity base, but its ROE has been volatile in recent quarters.

### 6. News and Recent Issues

* **Recent Earnings News:** [Provide links to articles from sources like Shacknews, etc. that discuss JNJ's latest earnings release] 
* **Market Outlook:** [Analyze and summarize the current market outlook for JNJ, including any recent analyst ratings and opinions from reputable sources like FINBOLD]

### 7. Summary and Conclusion

JNJ, while a well-established company, has faced challenges in recent months, with its stock price underperforming the market and recent earnings missing expectations. Its technical indicators suggest an oversold situation and a potential downtrend. However, JNJ continues to hold strong financial fundamentals, with robust profitability and a solid equity base. 

**Overall, JNJ presents a mixed picture. Investors should carefully consider its recent performance, market outlook, and the company's long-term growth potential before making any investment decisions.** 

### 8. Actionable Insights

* **Short-term:**  JNJ's current technical indicators suggest caution. 
* **Long-term:**  For investors with a long-term horizon and a belief in JNJ's long-term prospects, this dip could present an opportunity to accumulate shares.

**Note:** This is just an example of a stock analysis. Please conduct your own thorough research before making any investment decisions.